Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers Dongxue LiuLinlin HuHua Shao Review Article 06 July 2023 Pages: 165 - 179
Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer Gaoqi XuDihong YangLuo Fang Original Article 28 June 2023 Pages: 181 - 192
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors Mats NågårdMei-Lin Ah-SeeGanesh M. Mugundu Original Article Open access 02 July 2023 Pages: 193 - 203
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data Nastya KassirPhyllis ChanRené Bruno Original Article Open access 06 July 2023 Pages: 205 - 210
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo Dongbo WangHuina WuJing Nie Original Article 11 July 2023 Pages: 211 - 221
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab Emmanuelle JacquetFiona PhamNicolas Albin Original Article 13 July 2023 Pages: 223 - 228
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients M. ValeryK. SalehC. Castilla-Llorente Short Communication 24 June 2023 Pages: 229 - 233
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series Taro YamanakaKohji TakemuraYuji Miura Short Communication 28 June 2023 Pages: 235 - 240